This work aims at exploring the human CSF (Cerebrospinal fluid) N-glycome by MALDI MS techniques, in order to assess specific glycosylation pattern(s) in patients with Alzheimer's disease (n:24) and in subjects with mild cognitive impairment (MCI) (n:11), these last as potential AD patients at a pre-dementia stage. For comparison, 21 healthy controls were studied. We identified a group of AD and MCI subjects (about 40-50% of the studied sample) showing significant alteration of CSF N-glycome profiling, consisting of a decrease in the overall sialylation degree and an increase in species bearing bisecting GlcNAc. Noteworthy, all the MCI patients that converted to AD within the clinical follow-up, had an abnormal CSF glycosylation profile. Based on the studied cohort, CSF glycosylation changes may occur before an AD clinical onset. Previous studies specifically focused on the key role of glycosyltransferase GnT-Ill on AD-pathogenesis, addressing the patho-mechanism to specific sugar modification of BACE-1 glycoprotein with bisecting GlcNAc. Our patients addressed protein N-glycosylation changes at an early phase of the whole biomolecular misregulation on AD, pointing to CSF N-glycome analyses as promising tool to enhance early detection of AD and also suggesting alternative therapeutics target molecules, such as specific glyco-enzymes. (C) 2015 Elsevier B.V. All rights reserved.
|Titolo:||CSF N-glycoproteomics for early diagnosis in Alzheimer's disease|
|Data di pubblicazione:||2016|
|Citazione:||CSF N-glycoproteomics for early diagnosis in Alzheimer's disease / Palmigiano A; Barone R; Sturiale L; Sanfilippo C; Bua RO; Romeo DA; Messina A; Capuana ML; Maci T; Le Pira F; Zappia M; Garozzo D.. - In: JOURNAL OF PROTEOMICS. - ISSN 1874-3919. - 131(2016), pp. 29-37.|
|Appare nelle tipologie:||1.1 Articolo in rivista|